physiological role in volume and pressure homeostasis in humans.
In 1956, two separate experiments established the heart as an endocrine organ that synthesises ANP (Henry and Pearce, 1956; Kisch, 1956) . Increased cardiac expression and synthesis of ANP or ANP receptors was later found, which suggested a possible local paracrine function in a number of tissues including the eye (Gutkowska and Nemer, 1989; Sales et al., 1991) . Primary open-angle glaucoma (POAG) is a public health problem, which is the second leading cause of blindness worldwide (Coleman, 1999) . The percentage of affected individuals increases with age (e.g., 1.9% of Americans ³ 40-year-old affected, 7% ³80 years) and differs between populations (e.g., 3.6% Japanese ³40 years affected) (Libby et al., 2005) . The aetiology of POAG is unknown. Several risk factors have been found to be associated with the development of glaucoma. In the 1990s, the first major gene loci for POAG, GLC1A and GLC1B, were described (Gaspar et al., 1991; Dielemans et al., 1994) . The GLC1A gene encodes myocilin, the trabecular meshwork-induced glucocorticoid response protein. GLC1A is located on chromosome 1. Mutations in this gene cause raised eye pressure and damage to the optic nerve, but the underlying mechanisms are unknown (Dielemans et al., 1994) . Although raised intraocular pressure levels are usually associated with POAG, prediction of the progression from hypertension to glaucoma is difficult (Chauhan and Drance, 1992; Sheffield et al., 1993; Ruben et al., 1994; 1995) . Therefore, the identification of genetic markers may prove to be an important advance in the early diagnosis of glaucoma.
POAG is a heterogeneous disease, and elucidation of the underlying genetic mechanisms contributing to phenotypic expression is required for earlier diagnosis of individuals at risk and specific medical treatment. A positive family history of glaucoma is a risk factor. Autosomal dominant pedigrees have linked familial glaucoma to a region on chromosome 1 (1q21-1q 31) (Sheffield et al., 1993; Wiggs et al., 1994) , which contains the candidate gene, ANP-receptor A. Several studies have suggested that the ANP system plays a physiological role in the regulation of intraocular fluid homeostasis and intraocular pressure levels in the eye (Mittag et al., 1987; Nathanson, 1987; Diestelhorst and Kriegestein, 1989; Wolfensberger et al., 1994 , Tunny et al., 1996 . Immunohistochemical studies have localised ANP and BNP to the anterior segment of the eye (ciliary processes, anterior ciliary muscle) (Yamamoto et al., 1991; Palm et al., 1994) . The functional significance of the type B (ANP (B)) and type C (ANP (C)) natriuretic peptide receptors has been investigated in vivo in the rabbit eye by evaluating the effect of intracameral administration of C-type natriuretic peptide (CNP) and C-ANP-(4 -23) on intraocular pressure, and the action of CNP on guanylate cyclase activity in rabbit ciliary-process membranes (Fernandez-Durango et al., 1999) . ANP and BNP were also examined for comparison. This study demonstrated that the natriuretic peptides decrease intraocular pressure and stimulate guanylate cyclase activity, CNP being most potent. The expression of natriuretic peptides along with natriuretic peptides receptor transcripts in neural retinal, glial, and vascular elements of the normal adult retina suggests a role for these peptides in maintaining both the neural and vascular integrity of the mature retina (Rollin et al., 2004) .
The human ANP gene is localised on chromosome 1 (1p36) (Yang-Feng et al., 1985) . The gene is composed of three exons (Exon 1, Exon 2, and Exon 3) and two introns (Intron A and Intron B). Exon 1 (122 bp) contains the 5`-noncoding region, codon (AUG), 25 amino acid signal peptide sequence and pro-ANP 16 amino acid residues. Exon 2 (327 bp) contains the pro-ANP coding region, which is 125-amino acids long, and Exon 3 encodes the last pro-ANP aminoacid (Tyr). Exon 3 (302 bp) consists also of codon (UGA), the 3`-noncoding region and signal (AAUAAA). The six-nucleotide sequence of the pro-mRNA is recognised by a specific endonuclease. After cleavage of endonucleases, poly (A) polymerase synthesises an additional~250 adenine (A) residues. The ANP gene is 2710 nucleotide (nt)-long including Intron A (9122 bp) and Intron B (1110 bp) (Fig. 2) . Pro-ANP is stored in membrane-bound granules in atrial cardiocytes. Upon stimulation, these granules move to the cell surface, releasing the stored pro-ANP (1-126). The precise location and identity of this mechanism is still open to debate. This prohormone is cleaved into the mature 28 amino acid ANP, also known as ANP (1-28) or a-ANP, and the amino terminal fragment ANP (1-98). The 98 aminoacid N-terminus is further processed proteolytically within the circulation to form pro-ANP (1-30), pro-ANP (31-67) and pro-ANP (79-98) (Fig. 3) .
The main goals of the present study were to identify alterations in the ANP gene (genetic variations and promoter a structure) and to evaluate the pro-ANP level in the blood, in the search for a role of ANP in pathophysiological changes in patients with POAG. Additional aim of our research was to examine the relation between the level of hormone and increased intraocular pressure. We examined the ANP gene using a long-PCR based technique including PCR-RFLP analysis with various restriction endonucleases and PCR-SSCP to examine the 5`proximal promoter region of the gene (-595 to transcription start site), which is known to contain regulatory elements affecting gene transcription.
MATERIALS AND METHODS
We examined 27 patients with primary open-angle glaucoma (essential hypertension in 14 patients and normal blood pressure in 13 patients) and three patients without glaucoma and without blood hypertension as a control. Informed consent of all examined patients was obtained.
Intraocular pressure was measured in all patients on at least three separate occasions by calibrated Goldmann Applanation tonometry. The optic nerve head was examined by direct ophthalmoscopy and Volk 90 binocular slit lamp examination. Computerised visual field assessment was performed by Humphrey perimetry utilising the 30-2 programme.
Genomic DNA was extracted from peripheral blood leucocytes using the standard phenol-chloroform method as described in Sambrook et al. (1989) .
PCR-RFLP analysis of ANP gene. 1344 bp fragment of ANP gene was amplified by a long-PCR based method employing 50 ng of genomic DNA. For 1344 bp fragment amplification a 10 mM forward primer 5`-GGAAGTCAGCCCAGCCCAGAGAGAT -3`and 10 mM reverse primer 5`-GCAGTCTGTCCCTAGGCCCA-3`were used. The ANP gene sequence was taken from Gene Bank (code: K02043). PCR run times were: 2 min at 93°C, 1 min at 93°C, 1 min at 58°C, 1 min at 72°C, 30 cycles, and 10 minutes at 72°C. Amplification products were electrophoresed on 1% agarose gel and viewed under UV illumination. A negative control lane containing all reagents except DNA was run under identical PCR conditions for all gels.
Amplified products were digested at 37°C overnight using restriction enzymes SmaI and HpaII (Fermentas, Lithuania). Allelic frequencies at the RFLP sites in the ANP gene produced by SmaI and HpaII were analysed on 6% polyacrylamide gel. Besides PCR-RFLP analysis with restriction enzymes SmaI and HpaII, allelic frequencies at RFLP site in the ANP gene produced by ScaI were examined (Table 1) . For 478 bp fragment amplification the following primers were used: 10 mM forward primer 5'-TGAGGCAGGAGAATGGCGTGAA-3`and 10 mM reverse primer 5`-GCAGTCTGTCCCTAGGCCCA-3`.
PCR-SSCP analysis of the proximal promoter region of the ANP gene. For PCR-SSCP analysis the 211 bp fragment was amplified using forward primer 5`-CAGGTGTGAGGCCAGCTT-3`and reverse primer 5`-GGTTATCTCACCGCCGTG-3`. PCR conditions were: initial denaturation 5 min at 94°C, denaturation 1 min at 94°C, hybridisation 1 min at 62°C, elongation 90 s at 72°C, 30 cycles, final elongation 10 min at 72°C. PCR product sequencing. 211 bp PCR fragments before sequencing reaction were purified from agarose gel with a DNA Extraction kit (Fermentas, Lithuania). Purified 211 bp PCR fragments were sequenced using the Cycle Reader Immunoassay for the quantitative determination of pro-ANP in biological fluids (Biomedica). According to the manufacter's protocol, characteristic sizes of pro-ANP level were found to be lower than 1.32 nmol/ml with fluctuation 0-5 nmol/ml. Blood samples were collected from 30 patients: 14 patients had POAG and essential hypertension, 13 patients had POAG and normal blood pressure, and three patients were without glaucoma and with normal blood pressure.
RESULTS
Diagnosis of primary glaucoma was confirmed to all 27 patients, since two of three variables occurred simultaneously: intraocular pressure was consistently greater than or equal to 21 mm Hg, the optic nerve head cup: disc ratio was greather than or equal to 0.6, or glaucomatous visual field loss was characteristic. ScaI, NsiI Polymorphism of two alleles (2235 pos.) Masharami et al., 1988 SmaI, HpaII Polymorphism of two alleles (1834 pos.) Ramasawmy et al., 1992 XhoI, BglI Polymorphism of two alleles (1,6; 1,8) Berge et al., 1994 Of 27 glaucoma patients studied, to 24 (~90%) was observed elevated level of pro-ANP in plasma-2.3-42 nmol/ml (normal level is below 1.32 nmol/ml). Hovewer, 14 patients had POAG and essential hypertension. At the same time, there was elevated pro-ANP level in PAOG patients with normal haemodynamic indices. All patients without PAOG and hypertension were with a normal level of pro-ANP.
Successful amplification of 1344 bp structural gene and 478 bp promoter fragments of ANP gene have been performed and suitable for restriction cleavage pure amplicones obtained (Figs. 4 and 5) .
The produced fragments after digestion of the 1344 bp long fragments with HpaII are shown in Figure 6 . As it can be seen, no significant difference was observed in the frequency of the polymorphisms of ANP gene alleles and genotypes between the hypertensive patients and the control group. The PCR-RFLP analysis using Sca I restriction endonuclease and nucleotide sequencing of the ANP gene revealed a T2238®C transition within a stop codon in three hypertensive patients. No significant alterations in the 5p roximal promoter region of the ANP gene were observed also among hyperternsive patients.
DISCUSSION
The obtained results about pro-ANP level in blood and intraocular pressure suggest associations between POAG and natriuretic peptides (NP). More clearly such association may be evaluated by analysis of BNP and ANP in human aqueous humour, however this is an invasive method and therefore is not widely used (Salzmann et al., 1998) . Welldocumented increase of NP levels in hypertension and cardiac insufficiency from the other side limits using of peptide blood tests, but analysis of natriutretic peptides in normotensive patients should be recommended for introduction in ophthalmologic clinic. The immunoenzymatic methods (ELISA) are well suited for the determination of NP in patients with glaucoma, heart diseases and increased blood pressure, and it can be also used to diagnose the general condition of organism (Rubattu et al., 2006; Jeoung et al., 2007) .
Moreover, registered lowering of intraocular pressure upon intravitreally injected natriuretic peptide in rabbits strongly suggest that NP plays an important role in the control of intraocular pressure (Takashima et al., 1996) . Observed in our studies normal level of NP in blood of POAG patients may be considered as indication for using of NP in therapy hence. Mechanisms of NP level regulation in organism are still enigma, where gene structure or expression problems may be suspected. Our studies allow express such speculations, since T2238®C mutation within a stop codon of the ANP precursor gene was found in hypertensive patients. Anlysis of the promoter region, however, did not show any mutations or polymorphisms and our findings may suggest that the expression regulated elements in this promoter -595bp --384bp region are not connected with the development of hypertension and increased intraocular pressure. Therefore, our studies indicate the prospectivity of natriuretic peptide studies in glaucoma patients in order to get additional information about glaucoma pathogenesis and possible application of these peptides in therapy.
In conclusion:
· Using the PCR-RFLP method with ScaI restriction endonucleasis and sequencing analysis of the appropriate products, for three hypertensive samples, a mutation forming an arginine residue was found and localised in STOP codone (T2238®C). · PCR-SSCP method for polymorphism detection was employed using the 5'proximal promoter region of the gene. 
